Lexeo Therapeutics, Inc.
LXEO
$4.71
$0.7819.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -21.59% | 41.44% | |||
| Gross Profit | 21.59% | -41.44% | |||
| SG&A Expenses | 11.03% | 16.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.19% | 33.94% | |||
| Operating Income | 13.19% | -33.94% | |||
| Income Before Tax | 12.09% | -38.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 12.09% | -38.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.09% | -38.85% | |||
| EBIT | 13.19% | -33.94% | |||
| EBITDA | 13.23% | -34.14% | |||
| EPS Basic | 12.12% | -38.60% | |||
| Normalized Basic EPS | 12.04% | -38.59% | |||
| EPS Diluted | 12.12% | -38.60% | |||
| Normalized Diluted EPS | 12.04% | -38.59% | |||
| Average Basic Shares Outstanding | 0.04% | 0.19% | |||
| Average Diluted Shares Outstanding | 0.04% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||